Barclays raised the firm’s price target on Terns Pharmaceuticals (TERN) to $28 from $27 and keeps an Overweight rating on the shares following the Q3 report.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Promising Outlook for Terns Pharmaceuticals: Buy Rating Backed by Strong Financials and Potential Breakthrough in Leukemia Treatment
- Terns Pharmaceuticals reports Q3 EPS (27c), consensus (30c)
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright